Typical life expectancy with larotinib/larlotinib treatment

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions encode tropomyosin receptor kinase (TRK) fusion proteins and are oncogenic drivers in various tumor types. Larotrectinib (Larotrectinib) is a first-in-class, highly selective CNS-active TRK inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer.

Larotinib is mainly used to treat TRK fusion-positive malignant tumors. The type, stage and progression of the tumor will directly affect the patient's prognosis and lifespan. Patients who are diagnosed and treated early may have a better chance of survival. TRK fusion-positive malignancies are often associated with specific genetic mutations. Certain mutations may predict more severe disease progression and shorter lifespan. Therefore, the type and number of genetic mutations may have an impact on patient prognosis.

Larotinib has shown good efficacy in clinical trials, being able to significantly inhibit tumor growth and achieve complete remission in some patients. In a comprehensive analysis of 175 patients with non-primary central nervous system TRK fusion cancer, larotrectinib demonstrated an objective response rate (ORR) of 78% and a median progression-free survival (PFS) of 36.8 months. However, each patient's response to medication is individual, and treatment effects may vary from person to person. Some patients may continue to benefit, while others may develop resistance or disease progression.

The patient's overall health also has an impact on longevity. Other chronic diseases, physical conditions, and psychological states may affect a patient's tolerance and ability to recover, thereby affecting longevity. In addition to larotrectinib, patients' treatment options may also include other drugs, surgery, radiotherapy, etc. A comprehensive treatment strategy can improve a patient's chances of survival. The doctor will develop a treatment plan based on the patient's condition.